The Technical Analyst
Centessa Pharmaceuticals [CNTA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Centessa Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
3.25% $11.13
America/New_York / 16 apr 2024 @ 12:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 099.36 mill |
| EPS: | -1.570 |
| P/E: | -7.09 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 98.77 mill |
| Avg Daily Volume: | 0.397 mill |
| RATING 2024-04-15 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -7.09 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.21x |
| Company: PE -7.09 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.886 (-92.04%) $-10.24 |
| Date: 2024-04-16 |
| Expected Trading Range (DAY) |
|---|
|
$ 10.31 - 11.95 ( +/- 7.38%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-31 | Chao David M | Sell | 10 385 | Ordinary Shares |
| 2024-03-31 | Weinhoff Gregory M | Sell | 11 742 | Ordinary Shares |
| 2024-03-31 | Saha Saurabh | Sell | 36 263 | Ordinary Shares |
| 2024-03-31 | Hussain Iqbal J | Sell | 7 520 | Ordinary Shares |
| 2024-03-31 | Bush Tia L | Sell | 6 419 | Ordinary Shares |
| INSIDER POWER |
|---|
| 62.05 |
| Last 100 transactions |
| Buy: 3 998 584 | Sell: 832 725 |
Forecast:
13:39 - $10.98
Live Trading Signals (every 1 min)
Forecast
1: 12:09 - $11.16
Forecast 2: 12:59 - $11.23
Forecast 3: 13:39 - $10.98
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $11.13 (3.25% ) |
| Volume | 0.0412 mill |
| Avg. Vol. | 0.397 mill |
| % of Avg. Vol | 10.38 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CNTA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $7.51 | N/A | Active |
|---|
CNTA
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
Latest Press Releases
2024-03-28 16:28:00 - Press Release
Centessa Pharmaceuticals Reports Business Highlights And Financial Results For The Fourth Quarter And Full-year 2023
Boston and london, march 28, 2024 (globe newswire) -- centessa pharmaceuticals plc (nasdaq: cnta), a clinical-stage pharmaceutical company, today reported recent business highlights and financial results for the fourth quarter and full-year ended december 31, 2023.
2024-02-09 07:00:00 - Press Release
Centessa Pharmaceuticals To Present Additional 52-weeks Of Continuous Treatment Data From Third Year (part 5) Of Ongoing Phase 2a Study Of Serpinpc For The Treatment Of Hemophilia At The 17th Annual Congress Of The European Association For Haemophilia And Allied Disorders (eahad)
Boston & london, feb. 09, 2024 (globe newswire) -- centessa pharmaceuticals plc (nasdaq: cnta) announced that data from an additional 52-weeks of continuous treatment from the third year (part 5) of the ongoing phase 2a study of serpinpc for the treatment of hemophilia, will be presented during an oral presentation at the 17th annual congress of the european association for haemophilia and allied disorders (eahad) in frankfurt, germany, today, february 9, 2024. the company previously shared part 5 results during a poster presentation at the 65th american society of hematology (ash) annual meeting. serpinpc is an investigational subcutaneously administered novel inhibitor of activated protein c (apc) in registrational studies for the treatment for hemophilia b, with or without inhibitors.
2024-01-22 08:00:00 - Press Release
Centessa Pharmaceuticals To Participate In Upcoming Investor Conferences
Boston and london, jan. 22, 2024 (globe newswire) -- centessa pharmaceuticals plc (nasdaq: cnta), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:
2023-12-13 08:00:00 - Press Release
Centessa Pharmaceuticals To Present At The 42ⁿᵈ Annual J.p. Morgan Healthcare Conference
Boston and london, dec. 13, 2023 (globe newswire) -- centessa pharmaceuticals plc (nasdaq: cnta), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced its participation in the 42nd annual j.p. morgan healthcare conference in san francisco, ca. saurabh saha md phd, chief executive officer of centessa, is scheduled to present at the conference on wednesday, january 10, 2024, at 4:30 pm pst.
2023-12-10 12:05:00 - Press Release
Centessa Pharmaceuticals Announces New Data From An Additional 52-weeks Of Continuous Treatment From Third Year (part 5) Of Ongoing Phase 2a Study Of Serpinpc For The Treatment Of Hemophilia
Boston and london, dec. 10, 2023 (globe newswire) -- centessa pharmaceuticals plc (nasdaq: cnta), today announced new data from an additional 52-weeks of continuous treatment from the third year (part 5) of the ongoing phase 2a study of serpinpc for the treatment of hemophilia. the data were shared in a poster presentation at the american society of hematology (ash) annual meeting on sunday, december 10, 2023. serpinpc is an investigational subcutaneously administered novel inhibitor of activated protein c (apc) in registrational studies for the treatment for hemophilia b, with or without inhibitors.
Latest News
2024-03-18 20:01:33 - InvestorPlace
7 Biotech Stocks Ready to Ride the Sector's Resurgence
Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.
2024-02-09 07:00:00 - GlobeNewsWire
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
BOSTON & LONDON, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced that data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia, will be presented during an oral presentation at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in Frankfurt, Germany, today, February 9, 2024. The Company previously shared Part 5 results during a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting. SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) in registrational studies for the treatment for hemophilia B, with or without inhibitors.
2024-02-05 13:48:46 - Seeking Alpha
Centessa Pharmaceuticals: Clinical Advances And Unique Business Model Highlight Growth Potential
Centessa Pharmaceuticals: Clinical Advances And Unique Business Model Highlight Growth Potential
2023-12-26 10:31:09 - Zacks Investment Research
What Awaits These 4 Drug Stocks That More Than Doubled in 2023?
Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024.
2023-12-13 08:00:00 - GlobeNewsWire
Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference
BOSTON and LONDON, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Saurabh Saha MD PhD, Chief Executive Officer of Centessa, is scheduled to present at the conference on Wednesday, January 10, 2024, at 4:30 PM PST.
2023-11-02 09:09:00 - GlobeNewsWire
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
BOSTON and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that new data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia, will be presented during a poster session at the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, CA on December 10, 2023. SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) in registrational studies for the treatment for hemophilia B, with or without inhibitors.
2023-09-04 12:01:06 - Zacks Investment Research
Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why
Centessa (CNTA) shares rise significantly in the past three months due to the encouraging progress in the development of its lead pipeline candidate, SerpinPC, which is currently in mid-late-stage studies.
2023-08-23 17:08:00 - GlobeNewsWire
Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress
Oral presentation to include preclinical profile for ORX750, Centessa's first orexin agonist development candidate for the treatment of narcolepsy and other sleep disorders Oral presentation to include preclinical profile for ORX750, Centessa's first orexin agonist development candidate for the treatment of narcolepsy and other sleep disorders
2023-08-17 11:58:40 - Seeking Alpha
Centessa Pharmaceuticals: Pipeline Progresses As PRESent-2 Initiated
Centessa Pharmaceuticals takes a unique "asset-centric" approach in the biopharmaceutical industry, offering advantages such as reduced risk, improved efficiency, and greater potential for innovation. The company has a strong financial position with a cash reserve of $303.6 million and a projected runway extending operations into 2026. Centessa's product pipeline includes innovative therapies for hemophilia B, cancer, inflammatory diseases, and cystic fibrosis, with promising preliminary data and ongoing clinical trials.
2023-05-24 08:00:00 - GlobeNewsWire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON and LONDON, May 24, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: